What are the clinical indications for buspirone?

Clinical Indications for Buspirone

Buspirone is FDA-approved for the management of generalized anxiety disorder (GAD) and short-term relief of anxiety symptoms, with demonstrated efficacy in patients who have coexisting mild depressive symptoms. 1

Primary FDA-Approved Indication

Buspirone hydrochloride is indicated for:

• Generalized Anxiety Disorder (GAD): Patients with persistent anxiety lasting at least 1 month, manifested by motor tension, autonomic hyperactivity, apprehensive expectation, and vigilance/scanning 1
• Short-term anxiety relief: For symptoms associated with stress, though everyday stress typically does not require anxiolytic treatment 1

The FDA label specifically notes that buspirone has demonstrated efficacy in outpatients whose diagnosis corresponds to GAD, including those with coexisting depressive symptoms. Clinical trials enrolled patients with symptom duration averaging 6 months (range: 1 month to over 1 year) 1.

Evidence-Based Clinical Applications

Anxiety Disorders

• Chronic anxiety and mixed anxiety/depression states: Buspirone is particularly appropriate for patients with chronic anxiety or mixed anxiety-depressive symptoms 2, 3
• GAD with mild depression: Superior to placebo in improving both anxiety (12.4-point HAM-A reduction vs 9.5-point placebo reduction, p<0.03) and depressive symptoms (5.7-point HAM-D reduction vs 3.5-point placebo reduction, p<0.05) in patients with GAD and coexisting mild depressive symptoms (HAM-D scores 12-17) 4
• Anxious elderly patients: Well-tolerated with no sedation, cognitive impairment, or significant withdrawal symptoms 2, 5

Gastroparesis (Conditional Recommendation)

The 2025 AGA guideline suggests against buspirone as first-line treatment for gastroparesis (conditional recommendation, very low quality evidence), but notes that patients who value potential improvement in early satiety, postprandial fullness, and bloating may reasonably elect to use it 6. It may be considered as part of shared decision-making when patients have predominant early satiety and fullness 6.

Alzheimer's Disease-Related Agitation

Buspirone is listed as a nonbenzodiazepine anxiolytic option for mild to moderate agitation in Alzheimer's disease patients, though it requires 2-4 weeks to become effective. Dosing: initial 5 mg twice daily, maximum 20 mg three times daily 7.

Investigational/Off-Label Uses (Research Evidence)

• Cerebellar ataxia: Open-label study showed improvement in mild-to-moderate cerebellar dysfunction (up to 60 mg/day), though no benefit in severe cases 8
• Autism spectrum disorder: Low-dose buspirone (2.5 mg twice daily) showed significant improvement in restricted and repetitive behaviors in children aged 2-6 years (p=0.003), but higher doses (5 mg twice daily) showed no benefit 9
• Depression augmentation: STAR*D trial found similar efficacy when augmenting citalopram with buspirone versus bupropion SR, though buspirone had higher discontinuation rates due to adverse events (20.6% vs 12.5%, p<0.001) 10

Key Clinical Considerations

Advantages Over Benzodiazepines

• No sedation or cognitive/psychomotor impairment 2
• Low abuse potential with no cross-tolerance to benzodiazepines 1
• No significant withdrawal symptoms 2
• Does not potentiate alcohol-induced impairment (though concomitant use should be avoided) 1

Important Limitations

• Delayed onset: Takes 2-4 weeks for full anxiolytic effect 7
• Not appropriate for panic disorder: Studies have been inconclusive; not recommended for routine panic disorder treatment 3
• Will not prevent benzodiazepine withdrawal: Does not exhibit cross-tolerance with sedative/hypnotics, so patients must be gradually withdrawn from prior CNS depressants before starting buspirone 1

Dosing

• Standard dosing: 15 mg/day initially, typically given as 5 mg three times daily or 7.5 mg twice daily, with maximum doses up to 60 mg/day depending on indication 1
• Must be taken consistently either with or without food (food increases bioavailability 2-fold) 1, 11

Common Adverse Effects

Most frequent: dizziness (12%), drowsiness (10%), nausea (8%), headache (6%), nervousness (5%), and lightheadedness (3%) 1. Approximately 10% of patients discontinue due to adverse events, primarily CNS disturbances 1.